65.25
-0.25(-0.38%)
Currency In USD
| Previous Close | 65.5 |
| Open | 65.25 |
| Day High | 66.08 |
| Day Low | 64.85 |
| 52-Week High | 77 |
| 52-Week Low | 52.5 |
| Volume | 340,969 |
| Average Volume | 381,331 |
| Market Cap | 1.41B |
| PE | -55.3 |
| EPS | -1.18 |
| Moving Average 50 Days | 64.54 |
| Moving Average 200 Days | 60.57 |
| Change | -0.25 |
If you invested $1000 in ANI Pharmaceuticals, Inc. (ANIP) 10 years ago, it would be worth $1,044.84 as of July 01, 2025 at a share price of $65.25. Whereas If you bought $1000 worth of ANI Pharmaceuticals, Inc. (ANIP) shares 5 years ago, it would be worth $2,046.74 as of July 01, 2025 at a share price of $65.25.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ANI Pharmaceuticals Announces Presentation of New Preclinical Data
GlobeNewswire Inc.
Jun 12, 2025 11:00 AM GMT
The Use of Purified Cortrophin® Gel in Murine Collagen-Induced Arthritis Mouse Model presented as a poster at the European Alliance of Associations for Rheumatology (EULAR) 2025 CongressPRINCETON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- ANI Pharmac
ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
GlobeNewswire Inc.
May 27, 2025 8:30 PM GMT
PRINCETON, N.J., May 27, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 2025 Jefferies Global Healthcare Conference in New Yor
ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares
GlobeNewswire Inc.
May 22, 2025 10:50 AM GMT
Purified Cortrophin Gel is the only ACTH therapy approved by the FDA for the treatment of acute gout flares Trial to be conducted by Dr. Hyon Choi at Massachusetts General Hospital and will compare the safety and efficacy of two dose levels of Purifi